Recent research have focused on the convergence of GLP|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopamine neurotransmission. While GIP stimulators are increasingly employed for treating type 2 diabetes, their unexpected effects on motivation circuits, specifically